Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02317744 · ClinicalTrials.gov registry record · NA

Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo

A NA study, sponsored by Yale University.

Completed
Registry status
NA
Development phase
22
Enrollment target

NCT02317744: Completed NA study, sponsored by Yale University.

NCT02317744 is a NA study that has completed, run by Yale University. The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02317744, a NA study, has completed, sponsored by Yale University.

COMPLETED
Registry status
NA
Development phase
22 participants
Enrollment target

Study Summary

This study will test the effectiveness of the combination of Naltrexone and Bupropion relative to placebo for reducing binge eating in persons with obesity and binge eating disorder.

Primary Outcome

Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency also is defined continuously (analyzed dimensionally).

Interventions

  • DRUG Naltrexone and bupropion combination
  • OTHER Pill Placebo

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2014-12
Est. Completion 2016-09
Phase NA
Yale University

1,492 total trials

What the finished NCT02317744 record still lists

NCT02317744 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which Naltrexone and bupropion combination is the first listed.

NCT02317744 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02317744 about?

NCT02317744 is a clinical study titled "Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo". This study will test the effectiveness of the combination of Naltrexone and Bupropion relative to placebo for reducing binge eating in persons with obesity and binge eating disorder.

What is the current status of trial NCT02317744?

This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2014-12. Estimated completion is 2016-09.

What interventions are being tested in trial NCT02317744?

The interventions under investigation include: Naltrexone and bupropion combination (DRUG), Pill Placebo (OTHER).

Who is sponsoring clinical trial NCT02317744?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02317744's enrollment target sits among peer trials

22 1756th of 2000 higher than 239 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02317744, the US trial registry maintained by the National Library of Medicine. NCT02317744 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.